{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:20:09Z","timestamp":1791908409910,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04207-0","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T09:47:30Z","timestamp":1755769650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaofei","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaolin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"12","key":"4207_CR1","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3748\/wjg.v28.i12.1187","volume":"28","author":"M Ilic","year":"2022","unstructured":"Ilic M, Ilic I. Epidemiology of stomach cancer. World J Gastroenterol. 2022;28(12):1187\u2013203.","journal-title":"World J Gastroenterol"},{"issue":"16","key":"4207_CR2","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","volume":"29","author":"WJ Yang","year":"2023","unstructured":"Yang WJ, Zhao HP, Yu Y, Wang JH, Guo L, Liu JY, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023;29(16):2452\u201368.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"4207_CR3","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3748\/wjg.v22.i8.2403","volume":"22","author":"A Digklia","year":"2016","unstructured":"Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403\u201314.","journal-title":"World J Gastroenterol"},{"key":"4207_CR4","doi-asserted-by":"publisher","first-page":"175883592412294","DOI":"10.1177\/17588359241229428","volume":"16","author":"T Ogata","year":"2024","unstructured":"Ogata T, Narita Y, Oze I, Kumanishi R, Nakazawa T, Matsubara Y, et al. Chronological improvement of survival in patients with advanced gastric cancer over 15 years. Therapeutic Adv Med Oncol. 2024;16:17588359241229428.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"8","key":"4207_CR5","first-page":"Cd004064","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):Cd004064.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"4207_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"4207_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.","journal-title":"J Hematol Oncol"},{"key":"4207_CR8","doi-asserted-by":"publisher","first-page":"948647","DOI":"10.3389\/fimmu.2022.948647","volume":"13","author":"X Jin","year":"2022","unstructured":"Jin X, Liu Z, Yang D, Yin K, Chang X. Recent progress and future perspectives of immunotherapy in advanced gastric cancer. Front Immunol. 2022;13:948647.","journal-title":"Front Immunol"},{"key":"4207_CR9","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442.","journal-title":"Front Immunol"},{"issue":"2","key":"4207_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/imm.13755","volume":"172","author":"X Liu","year":"2024","unstructured":"Liu X, Zhao A, Xiao S, Li H, Li M, Guo W, et al. PD-1: A critical player and target for immune normalization. Immunology. 2024;172(2):181\u201397.","journal-title":"Immunology"},{"issue":"5","key":"4207_CR11","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"key":"4207_CR12","doi-asserted-by":"publisher","first-page":"1163633","DOI":"10.3389\/fimmu.2023.1163633","volume":"14","author":"RY Chen","year":"2023","unstructured":"Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633.","journal-title":"Front Immunol"},{"issue":"2","key":"4207_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4207_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"10294","key":"4207_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"8","key":"4207_CR16","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1111\/cas.15462","volume":"113","author":"K Yamaguchi","year":"2022","unstructured":"Yamaguchi K, Minashi K, Sakai D, Nishina T, Omuro Y, Tsuda M, et al. Phase IIb study of pembrolizumab combined with S-1\u2009+\u2009oxaliplatin or S-1\u2009+\u2009cisplatin as first-line chemotherapy for gastric cancer. Cancer Sci. 2022;113(8):2814\u201327.","journal-title":"Cancer Sci"},{"issue":"2","key":"4207_CR17","doi-asserted-by":"publisher","first-page":"548","DOI":"10.21037\/jgo-21-897","volume":"13","author":"M Xu","year":"2022","unstructured":"Xu M, Meng X, Lu Y, Wang F. Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer. J Gastrointest Oncol. 2022;13(2):548\u201358.","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"4207_CR18","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.4103\/jcrt.jcrt_856_21","volume":"17","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhao J, Yu H, Wang J, Zhang N, Cao B. Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma. J Cancer Res Ther. 2021;17(5):1234\u201340.","journal-title":"J Cancer Res Ther"},{"issue":"8","key":"4207_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"FH Wang","year":"2021","unstructured":"Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. 2021;41(8):747\u201395.","journal-title":"Cancer Commun"},{"issue":"1","key":"4207_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH Wang","year":"2024","unstructured":"Wang FH, Zhang XT, Tang L, Wu Q, Cai MY, Li YF, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 2024;44(1):127\u201372.","journal-title":"Cancer Commun"},{"issue":"3","key":"4207_CR21","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4207_CR22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ijc.34296","volume":"152","author":"T Liu","year":"2023","unstructured":"Liu T, Bai Y, Lin X, Li W, Wang J, Zhang X, et al. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: checkmate 649 Chinese subgroup analysis. Int J Cancer. 2023;152(4):749\u201360.","journal-title":"Int J Cancer"},{"issue":"1","key":"4207_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12876-023-03011-y","volume":"23","author":"X Huang","year":"2023","unstructured":"Huang X, He D, Lai L, Chen J, Zhang Y, Mao H. Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer. BMC Gastroenterol. 2023;23(1):374.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"4207_CR24","first-page":"3849","volume":"29","author":"ME Stegmann","year":"2021","unstructured":"Stegmann ME, Brandenbarg D, Reyners AKL, van Geffen WH, Hiltermann TJN, Berendsen AJ. Treatment goals and changes over time in older patients with non-curable cancer. Support Care Cancer. 2021;29(7):3849\u201356.","journal-title":"Support Care Cancer"},{"issue":"6","key":"4207_CR25","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.21037\/jgo-22-1229","volume":"13","author":"J Xiang","year":"2022","unstructured":"Xiang J, Gong W, Sun P, Wang X, Liu A. Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study. J Gastrointest Oncol. 2022;13(6):2874\u201384.","journal-title":"J Gastrointest Oncol"},{"key":"4207_CR26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2147\/OTT.S427942","volume":"16","author":"Z Chen","year":"2023","unstructured":"Chen Z, He Y, Ding C, Chen J, Gu Y, Xiao M, et al. Safety and efficacy analysis of PD-1 inhibitors in combination with gemcitabine plus Nab-Paclitaxel for advanced pancreatic cancer: A Real-World, Single-Center study. OncoTargets Therapy. 2023;16:923\u201335.","journal-title":"OncoTargets Therapy"},{"issue":"Pt A","key":"4207_CR27","doi-asserted-by":"publisher","first-page":"109317","DOI":"10.1016\/j.intimp.2022.109317","volume":"113","author":"M Noori","year":"2022","unstructured":"Noori M, Mahjoubfar A, Azizi S, Fayyaz F, Rezaei N. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: a systematic review and meta-analysis. Int Immunopharmacol. 2022;113(Pt A):109317.","journal-title":"Int Immunopharmacol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04207-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04207-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04207-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:31:05Z","timestamp":1757478665000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04207-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4207"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04207-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Board of the Department of Oncology, Anqing 116 Hospital. All procedures were followed in accordance with the Declaration of Helsinki under the Ethics approval. Each participant signed the informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"609"}}